S-Ketamine Preserves Oxidative Metabolism and Reduces Metabolic Stress During Neuronal Hyperexcitability
Georg Riepe, Jonas Schunack, Jörg Rösner, Iwona Wallach, Nikolaus Berndt, Agustin Liotta · 2026
Read S-Ketamine Preserves Oxidative Metabolism and Reduces Metabolic Stress During Neuronal Hyperexcitability by Georg Riepe, Jonas Schunack, Jörg Rösner, Iwona Wallach, Nikolaus Berndt, Agustin Liotta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607510.txt.
Introduction
Georg Riepe and co-authors measure how the anesthetic S-ketamine affects brain cell energy use during calm and overexcited states, in mouse brain slices in a 2026 study. The drug is used more and more in anesthesia and critical care, with hints that it calms seizures and protects the brain. Overexcited neurons burn far more oxygen, so the team tracked oxygen use, ion flows, and a mitochondrial glow signal.
At a moderate dose the drug left normal activity untouched, slightly eased energy use during rhythmic firing, and abolished seizure-like events while bringing oxygen use back to baseline. Higher doses dampened responses by quieting activity, not by starving cells. The profile supports protective use in hyperexcited states.
Catalog record
| CREATOR | Georg Riepe, Jonas Schunack, Jörg Rösner, Iwona Wallach, Nikolaus Berndt, Agustin Liotta |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
S-Ketamine Preserves Oxidative Metabolism and Reduces Metabolic Stress During Neuronal Hyperexcitability Authors: Georg Riepe, Jonas Schunack, Jörg Rösner, Iwona Wallach, Nikolaus Berndt, Agustin Liotta Published: 2026 ABSTRACT S-ketamine is increasingly used in anesthesia and neurocritical care and has been associated with anticonvulsant and potentially neuroprotective effects. Such neuroprotective effects have been observed particularly in states of severe hyperexcitability, including status epilepticus and spreading depolarizations, in which neuronal energy demand rises sharply and mitochondrial function may become compromised. However, the direct effects of S-ketamine on neuronal oxidative metabolism across different activity states remain incompletely understood. In acute hippocampal slices from 6–12-week-old male and female C57BL/6 mice, cerebral metabolic rate of oxygen (CMRO2) was quantified using depth-resolved tissue oxygen measurements under baseline conditions, during electrical stimulation, kainate-induced gamma oscillations, and Mg2+-free-induced epileptiform activity. Extracellular potassium dynamics and flavin adenine dinucleotide autofluorescence were recorded to assess neuronal excitability and mitochondrial redox state. S-ketamine was tested at concentrations of 100–1000 µM, and findings were integrated with computational modeling. At 100 µM, S-ketamine did not alter basal or stimulus-evoked CMRO2 or extracellular potassium handling. During gamma oscillations, S-ketamine modestly reduced CMRO2 and decreased oscillation frequency. Under Mg2+-free conditions, S-ketamine abolished seizure-like events and normalized CMRO2 to pre-Mg2+-free levels. Higher concentrations suppressed stimulus-evoked metabolism and attenuated mitochondrial redox responses, consistent with reduced neuronal activity rather than acute energy failure. These findings demonstrate an activity-dependent neurometabolic profile of S-ketamine characterized by preservation of oxidative metabolism under physiological conditions and reduced metabolic stress during pathological hyperexcitability. 1. Introduction The brain is among the most energetically demanding organs, accounting for approximately 20% of total oxygen consumption at rest [1]. A substantial proportion of neuronal adenosine triphosphate (ATP) production is required to maintain transmembrane ion gradients and sustain synaptic transmission and network activity [2]. Therefore, neuronal function critically depends on a continuous supply of oxygen and glucose, rendering the brain particularly vulnerable to disturbances in energy metabolism [3]. Even modest impairment of oxidative metabolism can disrupt synaptic signaling, promote excitotoxic injury, and precipitate acute or delayed neurological dysfunction [2]. During pathological neuronal hyperexcitability, sustained discharges and the subsequent restoration of transmembrane ion gradients sharply increase ATP demand, which is met predominantly by mitochondrial oxidative phosphorylation, with an additional contribution from glycolysis [2]. In parallel, neuronal activity triggers neurovascular signaling involving neurotransmitter- and metabolite-dependent pathways, including nitric oxide, prostaglandins, adenosine, and K+, which increase local cerebral blood flow and thereby oxygen and substrate delivery [4]. Astrocyte–neuron metabolite exchange further supports the increased metabolic demand [2,3]. When the demand exceeds oxidative capacity, the resulting energy deficit impairs ion homeostasis and inhibitory interneuron function, leading to metabolic and excitatory disturbances that may reinforce one another [5,6]. General anesthetics profoundly alter neuronal activity, cerebral perfusion, and mitochondrial function, thereby directly affecting cerebral energy metabolism [7,8,9]. Reflecting these actions on neuronal excitability, many of these agents also exhibit intrinsic anticonvulsant properties, most commonly by potentiating γ-aminobutyric acid type A (GABAA) receptor-mediated inhibition (e.g., propofol, barbiturates, and volatile anesthetics) or by antagonizing excitatory N-methyl-D-aspartate (NMDA) receptors [10]. However, several anesthetics act as anticonvulsants only at specific doses [11], and some volatile agents such as sevoflurane can even become proconvulsant at high concentrations [12,13]. While suppression of neuronal activity and metabolic demand underlies the neuroprotective rationale for anesthesia in conditions such as traumatic brain injury or refractory status epilepticus, anesthetic-induced alterations in neurovascular coupling or mitochondrial respiration may conversely create states of energetic mismatch. Such metabolic vulnerability has been implicated in postoperative neurological complications, including delirium and long-term cognitive impairment [14,15]. A detailed understanding of how individual anesthetic agents modulate neuronal oxidative metabolism is therefore essential to distinguish metabolically adaptive from potentially harmful effects [9]. S-ketamine, the S-enantiomer of ketamine and a noncompetitive NMDA receptor antagonist, occupies a unique position among anesthetic agents and has gained increasing attention in neurocritical care and perioperative medicine [16,17,18]. Clinically, S-ketamine has been associated with reduced spreading depolarizations after subarachnoid hemorrhage [19,20], effective seizure suppression in refractory status epilepticus [21], and a lower incidence of postoperative delirium [22]. These observations have raised interest in its potential neuroprotective profile, particularly under conditions of pathological neuronal hyperactivity. Experimental studies suggest that ketamine may modulate multiple cellular pathways implicated in neuroprotection, including excitotoxic signaling, oxidative stress, inflammation, and mitochondrial function [23,24,25]. Conversely, evidence of ketamine-induced mitochondrial dysfunction and neurotoxicity has also been reported, particularly at high concentrations or with prolonged exposure [26,27,28,29,30]. These seemingly contradictory findings underscore the context- and dose-dependent nature of ketamine’s effects. A systematic evaluation across a broad concentration range is therefore essential to delineate metabolically safe from potentially harmful effects. Despite the extensive clinical and experimental literature, little is known about the acute effects of S-ketamine on neuronal oxidative metabolism itself. Most prior studies rely on indirect markers of mitochondrial function [29,30,31], histological outcomes [26], or long-term behavioral measures [32], whereas direct real-time measurements of cerebral oxygen consumption are lacking. In previous work, we demonstrated that anesthetic agents differ fundamentally in their metabolic profiles: propofol can directly impair mitochondrial respiration, whereas volatile anesthetics primarily reduce energy demand through activity-dependent mechanisms [33,34,35]. Here, we aimed to define the neurometabolic profile of S-ketamine using an integrative ex vivo and in silico approach. Acute hippocampal slices allow direct measurement of neuronal oxidative metabolism under controlled oxygen and substrate supply, thereby minimizing confounding effects of systemic variables. In this study, we quantified cerebral metabolic rate of oxygen (CMRO2) across distinct activity states, including baseline conditions, physiological gamma oscillations, and epileptiform activity. We integrated these measurements with computational modeling of ATP dynamics and mitochondrial redox state. This approach allowed us to distinguish activity-dependent from potential direct metabolic effects of S-ketamine. We hypothesized that S-ketamine exerts a distinctive, activity-dependent metabolic profile that may underlie its clinical neuroprotective effects and distinguish it from other anesthetic agents. 2. Results Data from both male and female animals were included in all experiments. Separate analyses for male and female animals revealed consistent directionality and comparable statistical significance of all main effects (Supplementary Tables S1–S6); data were therefore pooled for the main analyses. 2.1. S-Ketamine (100 µM) Does Not Affect Cerebral Metabolic Rate of Oxygen (CMRO2) or Potassium Handling in Naïve Slices To assess whether S-ketamine alters neuronal energy metabolism at pharmacologically effective concentrations, we quantified CMRO2, modeled ATP consumption, and extracellular potassium ([K+]o) dynamics in hippocampal CA1 slices before and after application of 100 µM S-ketamine (Figure 1). Measurements were performed under baseline conditions and during brief electrical stimulation. During baseline recordings, oxygen consumption remained stable at 17.90 mmHg·s−1 (14.80–21.97) before and 19.10 mmHg·s−1 (15.83–24.39) after S-ketamine application (n = 22; Wilcoxon signed-rank test, p = 0.548). Correspondingly, normalized CMRO2 changed non-significantly by 2.91% and modeled ATP consumption by 1.66% (Figure 1b,c). Following tetanic stimulation (20 Hz, 2 s), CMRO2 increased to 20.42 mmHg·s−1 (17.53–25.79) before and 20.77 mmHg·s−1 (16.95–27.79) after drug application (n = 21; Wilcoxon signed-rank test, p = 0.848). The normalized response showed no significant effect (+1.52%), and modeled ATP consumption remained unchanged (+0.75%; Figure 1b,c). Time-control experiments confirmed that basal and stimulus-induced CMRO2 remained stable over repeated measurements, excluding time-dependent drift (Supplementary Figure S2). Stimulus-evoked [K+]o transients were analyzed to assess neuronal excitability. Amplitudes were significantly reduced in both the untreated control group to 82.29% (74.23–92.06;